https://www.biopharmawatch.com/news/FRNM/freenome-new-validation-data-crc-screening-test-acg-2026 BiopharmaWatch en 2026-10-11T17:00:00.000Z Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 https://www.biopharmawatch.com/news/BBIO/encaleret-phase-3-calibrate-trial-results BiopharmaWatch en 2026-10-11T15:42:00.000Z Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) https://www.biopharmawatch.com/news/IART/integra-announces-pricing-senior-secured-notes BiopharmaWatch en 2026-10-09T21:22:00.000Z Integra Announces Pricing of Senior Secured Notes https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261009 BiopharmaWatch en 2026-10-09T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/BMGL/basel-medical-group-ltd-closes-registered-direct-offering BiopharmaWatch en 2026-10-09T20:32:00.000Z Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering https://www.biopharmawatch.com/news/GDTC/cytomed-therapeutics-nasdaq-notification-minimum-bid-price BiopharmaWatch en 2026-10-09T20:30:00.000Z CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency https://www.biopharmawatch.com/news/CCEL/cryo-cell-reports-fiscal-q3-2026-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVH/evolent-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grant-nyse-american BiopharmaWatch en 2026-10-09T20:15:29.000Z AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-1-15-billion-offerings BiopharmaWatch en 2026-10-09T20:05:09.000Z Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes https://www.biopharmawatch.com/news/ACH/accendra-health-nyse-listing-standard-notice BiopharmaWatch en 2026-10-09T20:05:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-09T20:05:00.000Z Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ASTH/astrana-health-q3-financial-results-2026 BiopharmaWatch en 2026-10-09T20:05:00.000Z Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/MGRX/mangoceuticals-closes-direct-offering-premium BiopharmaWatch en 2026-10-09T20:01:00.000Z Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close https://www.biopharmawatch.com/news/MLAB/mesa-labs-quarterly-dividend-announcement BiopharmaWatch en 2026-10-09T20:00:00.000Z MESA LABS DECLARES QUARTERLY DIVIDEND https://www.biopharmawatch.com/news/AGEN/agenus-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-09T19:23:00.000Z Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference